BioNTech (BNTX) vs Exelixis (EXEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Exelixis (EXEL) has outperformed BioNTech (BNTX) over the past year, gaining 52.7% versus a loss of 13.4%. Over five years, EXEL leads with a +170.5% price change compared with -62.8% for BNTX. BioNTech is the larger company by market cap ($23.13 billion vs $14.62 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | EXEL |
|---|---|---|
| Share price | $92.06 | $59.02 |
| Market cap | $23.13B | $14.62B |
| 1-day change | -3.35% | +0.99% |
| YTD return | -3.30% | +34.66% |
| 1-year return | -13.38% | +52.74% |
| 5-year return | -62.83% | +170.49% |
| P/E ratio (TTM) | — | 18.62 |
| Forward P/E | — | 13.92 |
| EPS (TTM) | $-7.83 | $3.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.32B |
| Revenue growth (YoY) | — | +6.98% |
| Net income (latest FY) | — | $782.57M |
| Gross margin | — | 96.39% |
| Operating margin | — | 37.59% |
| Net margin | — | 33.73% |
| 52-week high | $124.00 | $61.14 |
| 52-week low | $79.52 | $33.76 |
| Distance from 52-week high | -25.76% | -3.47% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +25.78% | -7.61% |
| Average volume | 1.16M | 2.34M |
| Shares outstanding | 251.20M | 247.78M |
| Employees | 7,807 | 1,077 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EXEL has outperformed BNTX by 66.1 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
BNTX vs EXEL FAQ
Which is bigger, BioNTech or Exelixis?
BioNTech (BNTX) is larger, with a market capitalization of $23.13B compared with $14.62B for Exelixis (EXEL).
Which stock has performed better over the past year, BNTX or EXEL?
EXEL returned +52.74% over the past 12 months, compared with -13.38% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Exelixis in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.